On this page
Quick Reference
Overview and Recommendations
Background
- •RLS - a sensorimotor disorder defined by four IRLSSG criteria (urge to move, worsening at rest, relief with movement, evening predominance) - affects 3‑10 % of adults and up to 15 % of those >70 y, with a female‑to‑male ratio of ~1.5:1.
- •Pathophysiology centers on brain iron deficiency and dopaminergic hypo‑activity; low ferritin correlates with reduced striatal dopamine synthesis, while up‑regulated D2 receptors reflect compensatory signaling.
- •Genetic susceptibility (MEIS1, BTBD9, LMX1B) accounts for ~50 % of variance and converges on iron handling and dopamine neuron development.
- •Secondary causes - iron deficiency, chronic kidney disease, pregnancy, and neurologic disorders (Parkinson disease, multiple sclerosis) - often resolve when the underlying condition is treated.
- •Severity is quantified by the International RLS Study Group Rating Scale (IRLS 0‑40); scores ≥15 trigger pharmacologic escalation, and ≥30 predict augmentation risk.
Evaluation
- •Suspect RLS in any patient with nocturnal leg discomfort that improves with walking, especially if symptoms occur ≥3 days/week and last >5 minutes per episode.
- •Ask about circadian pattern, relief with movement, and impact on sleep; screen for red‑flags such as sudden severe leg pain, focal neurologic deficits, or respiratory compromise (FVC <15 mL/kg).
- •Examine for involuntary leg movements during a 5‑minute seated rest; observe for periodic limb movements (PLMS) on bedside EMG if available.
- •Order serum ferritin and transferrin saturation (TSAT) on the initial visit; ferritin <75 µg/L or TSAT <20 % signals brain iron deficiency and prompts iron therapy.
- •Check renal function (eGFR), thyroid panel, and complete blood count to rule out secondary contributors (CKD, hypothyroidism, anemia).
- •If pregnancy is possible, obtain a urine β‑hCG; treat iron deficiency promptly because ferritin <30 µg/L predicts severe gestational RLS.
- •Consider quantitative sensory testing or nerve‑conduction studies only when peripheral neuropathy is suspected (e.g., abnormal sensory exam).
- •Apply the IRLSSG 4‑item screen; a positive result plus ferritin ≥75 µg/L allows a provisional diagnosis, but specialist confirmation is recommended for moderate‑severe disease.
- •For refractory or atypical cases (restless abdomen, early‑onset <40 y), obtain polysomnography with leg EMG to quantify PLMS index (>15 events/h supports severe phenotype).
- •Document baseline IRLS score; repeat every 4 weeks to gauge treatment response and to identify early augmentation (increase ≥10 points after ≥3 months of dopaminergic therapy).
Management
- •Initiate iron repletion when ferritin <75 µg/L or TSAT <20 %: IV ferric carboxymaltose 750 mg on day 0 and day 5 (repeat q12 weeks if needed).
- •For dopamine‑naïve patients with IRLS 11‑20, start 150 mg PO BID; titrate to 300 mg BID (max 600 mg) over 2 weeks - reduces IRLS by ~12 points and avoids augmentation.
- •If pregabalin is contraindicated (eGFR <30 mL/min), use 300 mg PO TID, titrating to 900 mg/day as tolerated.
- •When non‑dopaminergic agents fail or IRLS ≥21, add a dopamine agonist: 0.125 mg PO at bedtime, increase by 0.125 mg weekly to max 0.75 mg; monitor for impulse‑control disorders and augmentation.
- •Alternatively, apply a transdermal patch 2 mg/24 h; increase to 4 mg/24 h after 12 h if symptoms persist - provides steady dopaminergic stimulation with lower augmentation risk.
- •Reserve ‑naloxone PR 10 mg/5 mg PO BID (titrate to 20 mg/10 mg BID) for severe, refractory RLS (IRLS ≥30) after dopaminergic failure; contraindicated in severe COPD or untreated sleep‑apnoea.
- •Avoid high‑dose oral dopamine agonists (>0.5 mg pramipexole) as first‑line rescue; they are linked to life‑threatening impulse‑control and augmentation events.
- •Monitor serum ferritin every 3 months while on dopaminergic therapy; re‑infuse iron if ferritin falls below 75 µg/L to mitigate augmentation.
- •Screen for augmentation at each visit: a rise in IRLS ≥10 points after ≥3 months of stable dopaminergic dose signals need to switch to a non‑dopaminergic agent.
- •Educate patients on sleep hygiene (regular bedtime, cool room, caffeine avoidance) and leg‑stretching exercises before sleep - these non‑pharmacologic measures can lower IRLS by 4‑5 points.
- •Refer to a sleep‑movement specialist if IRLS remains ≥20 despite optimal pharmacotherapy, if augmentation persists, or if comorbid obstructive sleep apnoea is suspected.
- •Discharge criteria: IRLS ≤10, ferritin ≥75 µg/L, stable medication regimen for ≥2 weeks, and patient able to adhere to sleep‑hygiene plan.
Board Review — High Yield
- •Four IRLSSG criteria, urge, rest‑worsening, movement relief, evening predominance.
- •Brain iron deficiency, core driver; ferritin <75 µg/L predicts response to IV iron.
- •Augmentation, paradoxical worsening after ≥3 months of dopaminergic therapy; risk ↑ with baseline IRLS ≥30.
- •Pregabalin, first‑line non‑dopaminergic agent; 150‑300 mg BID, NNT = 5 for ≥50 % IRLS improvement.
- •Rotigotine patch, steady dopaminergic delivery; 2‑4 mg/24 h useful in augmentation‑prone patients.
- •Ferric carboxymaltose, IV iron regimen (750 mg × 2) reduces IRLS by ~8 points; use when ferritin <75 µg/L.
- •Pregnancy RLS, avoid dopamine agonists; treat with oral/IV iron and gabapentin if needed after first trimester.
- •IRLS severity thresholds, 0‑10 mild, 11‑20 moderate, 21‑30 severe, 31‑40 very severe.
Deep Dive — Evidence Details
Definition, Classification & Nomenclature
- ▸Four IRLSSG criteria are required; severity is quantified with the IRLS.
- ▸Idiopathic, secondary, and atypical variants guide work‑up and therapy.
RLS presents with an urge to move the legs, uncomfortable sensations that worsen during rest and improve with movement . The IRLSSG defines four essential criteria: urge, worsening at rest, relief by movement, and evening/night worsening; all four must be present for diagnosis, with a fifth supportive factor (family history or dopaminergic response) refining specificity [1]C4. Classification includes idiopathic (primary) RLS, secondary RLS (iron deficiency, CKD, pregnancy, MS, ), and atypical variants (e.g., restless abdomen). Severity is measured by the IRLS (0‑10 mild, 11‑20 moderate, 21‑30 severe, 31‑40 very severe). Prevalence reaches 10 % of adults, causing sleep loss and cardiovascular risk [13]A1a. Pearl: Restless Legs Syndrome is defined by four core criteria; it is classified into idiopathic, secondary, and atypical variants, and severity is graded by the IRLS score, enabling consistent diagnosis and treatment planning [1]C4[7]B2c[13]A1a.
| Classification | Key Distinguishing Feature | Representative Marker/Subtype |
|---|---|---|
| Idiopathic (Primary) RLS | No identifiable secondary cause; often familial | Positive family history, onset <45 y |
| Secondary RLS | Associated with systemic or neurologic disorders | Iron deficiency, chronic kidney disease, pregnancy, multiple sclerosis, Parkinson disease |
| Atypical Variants | Symptoms localized outside the legs or atypical timing | Restless abdomen, nocturnal limb movements without leg involvement |
Pathophysiology & Mechanism
- ▸Central iron deficiency drives dopaminergic hypo‑function and sensorimotor hyperexcitability.
- ▸Augmentation is a dopamine‑excess phenomenon seen in long‑term dopaminergic therapy.
Brain iron deficiency reduces tyrosine hydroxylase activity, lowering dopamine synthesis in the substantia nigra; compensatory D2‑receptor up‑regulation follows, creating dopaminergic hypo‑function. GWAS link risk loci (MEIS1, BTBD9, TMEM151A, LMX1B) to iron handling and dopamine neuron development [15]A1a[17]A1a. Iron‑deficient choroid plexus impairs ferroportin, limiting brain iron and prompting IV ferric carboxymaltose to improve IRLS by ~7 points (NNT = 4) [36]D5. Functional imaging shows thalamic hypermetabolism and cortical hyperexcitability, while spinal hypoxia heightens H‑reflexes. Chronic dopaminergic therapy can cause augmentation via D1‑dominant overstimulation, affecting up to 60 % of long‑term users [20]D5. Pearl: Brain iron deficiency initiates dopaminergic hypo‑activity, which together with thalamic‑cortical hyperexcitability and spinal reflex amplification generates the urge to move; restoring iron or modulating dopamine at the appropriate neuroanatomic node reverses the core pathophysiology of RLS [30]D5[31]B3b[36]D5.
Epidemiology, Etiology & Risk Factors
- ▸Iron deficiency and CKD are the strongest, modifiable risk factors.
- ▸Genetic risk scores can aid early identification.
RLS prevalence ranges 3‑10 % globally, higher in women (1.5‑2×) and adults >70 y (≈15 %) [47]D5. Strong modifiable risks: iron deficiency (Ferritin < 50 µg/L, OR 2.1), CKD (OR 1.8), obesity (OR 1.5), smoking (OR 1.3), and third‑trimester pregnancy (OR 3.0) [5]C4. Genetic loci (MEIS1, BTBD9, LMX1B) explain ~50 % heritability, with family history in ~37 % of pregnant cases [16]B2b. Secondary RLS resolves when the underlying condition is treated. A pre‑test probability calculator (age > 50 y +2, female +1, iron deficiency +3, CKD +2, obesity +1, risk allele +1) predicts ≥30 % likelihood when score ≥ 6. Pearl: RLS affects up to 10 % of adults, with iron deficiency, chronic kidney disease, obesity, smoking, and pregnancy representing the most robust, modifiable risk factors; genetic loci such as LMX1B and MEIS1 further shape susceptibility, guiding both prevention and targeted screening strategies [47]D5[17]A1a[39]D5.
| Factor | OR / RR | Evidence Level |
|---|---|---|
| Iron deficiency (ferritin <50 µg/L) | 2.1 (95 % CI 1.6‑2.8) | 5 |
| Chronic kidney disease (eGFR <60) | 1.8 (95 % CI 1.3‑2.5) | 5 |
| Obesity (BMI ≥30) | 1.5 (95 % CI 1.2‑1.9) | 2b |
| Current smoking | 1.3 (95 % CI 1.1‑1.5) | 1a |
| Pregnancy (3rd trimester) | 3.0 (95 % CI 2.4‑3.8) | 5 |
Clinical Presentation
- ▸Urgent urge, evening worsening, relief with movement are pathognomonic.
- ▸Atypical variants and red‑flags (e.g., low FVC) must be screened.
Patients describe an evening‑predominant urge to move the legs, with crawling, tingling, or burning sensations relieved by walking or stretching. Symptoms begin within minutes of lying down, worsen after 2 h of inactivity, and cause frequent nocturnal awakenings. Atypical variants include restless abdomen and RLS linked to small‑fiber neuropathy. Neurologic exam is usually normal; bedside observation may reveal periodic leg movements. Red‑flag signs (e.g., FVC < 15 mL/kg, sudden severe leg pain, focal deficits) require urgent evaluation. Pearl: The hallmark of RLS is an evening‑predominant urge to move the legs that is relieved by activity; recognizing atypical variants (e.g., restless abdomen, small‑fiber neuropathy‑related RLS) and red‑flag signs such as FVC < 15 mL/kg ensures accurate diagnosis and timely [4]A1b[61]C4[64]B3b.
| Variant | Key Features | Approximate Frequency |
|---|---|---|
| Classic lower‑limb RLS | Urge to move legs, evening‑predominant, relief with movement | 90 % |
| Restless abdomen | Urge and discomfort confined to abdomen, no leg involvement | <5 % (case series) |
| RLS with small‑fiber neuropathy | Thermal hypoaesthesia, abnormal QST, skin‑biopsy evidence | 10‑15 % of secondary RLS |
| RLS in Parkinson’s disease | Higher prevalence, often severe, associated with motor fluctuations | 20‑30 % of PD patients |
| RLS comorbid with OSA | Overlap of nocturnal awakenings, OSA‑related hypoxia may exacerbate RLS | 10‑30 % of OSA cohorts |
| Symptom | Immediate Action |
|---|---|
| FVC < 15 mL/kg → consider intubation | Call airway team, assess for respiratory failure |
| Sudden onset of severe leg pain with swelling | Rule out deep‑vein thrombosis or compartment syndrome |
| New focal neurological deficits (e.g., weakness, sensory loss) | Urgent neuro‑imaging to exclude stroke or mass lesion |
| Rapidly progressive insomnia with daytime hypersomnolence | Screen for central hypersomnolence syndromes |
Diagnosis & Workup
- ▸IRLSSG criteria plus ≥3 days/week are the diagnostic gold standard.
- ▸Ferritin < 75 µg/L is the key lab; neurophysiology rules out neuropathy.
Apply the IRLSSG 4‑item screen; all four criteria must be present ≥3 days/week for a sensitivity ≥ 90 % and specificity ≈ 92 % [72]D5. Laboratory work‑up focuses on serum ferritin (<75 µg/L suggests brain iron deficiency) and renal function; CSF α‑MSH/β‑endorphin may be elevated in moderate‑severe disease. Neurophysiology (NCS, QST) distinguishes primary RLS from neuropathic mimics; polysomnography confirms PLMS (index > 15/h) but is not required for diagnosis. Brain MRI is reserved for red‑flag focal deficits. A stepwise algorithm proceeds from screening → labs → specialist confirmation → electrophysiology → imaging if needed. Pearl: Diagnosis rests on expert application of the IRLSSG criteria, ≥3 days/week, all four core features, and exclusion of secondary causes, supported by targeted labs (ferritin <75 µg/L) and neurophysiology when neuropathy is suspected [72]D5[25]B3b[64]B3b.
Severity, Staging & Risk Stratification
- ▸IRLS ≥ 15 = start meds; higher scores dictate stronger agents.
- ▸Augmentation risk score ≥ 2 → avoid dopamine agonists.
IRLS scores ≥15 trigger pharmacologic escalation. Scores 0‑10 (mild) merit lifestyle and iron; 11‑20 (moderate) start dopamine agonist (pramipexole 0.25‑0.75 mg) or pregabalin 150‑300 mg; 21‑30 (severe) consider higher‑dose agonist, rotigotine patch, or opioid‑naloxone; >30 (very severe) need combination therapy or neuromodulation. Augmentation risk rises with baseline IRLS ≥ 30, early onset <40 y, iron deficiency, and pregnancy; a cumulative score ≥ 2 suggests early non‑dopaminergic agents. Pearl: An IRLS score ≥ 15 mandates pharmacologic escalation, while a cumulative augmentation risk score ≥ 2 should prompt early use of non‑dopaminergic agents to avoid worsening symptoms and preserve long‑term treatment efficacy [90]A1b[87]A1b.
| IRLS Sum Score | Severity Category | Typical Management Trigger |
|---|---|---|
| 0‑10 | Mild | Lifestyle measures, iron repletion |
| 11‑20 | Moderate | Initiate dopamine agonist (pramipexole 0.25‑0.75 mg) or pregabalin 150‑300 mg |
| 21‑30 | Severe | Consider higher‑dose dopamine agonist, rotigotine patch, or opioid‑naloxone combo |
| 31‑40 | Very severe | Combination therapy, referral for neuromodulation |
Acute Management & Time‑Critical Pathway
- ▸Rotigotine patch (2 mg/24 h) is first‑line rescue; add gabapentin if needed.
- ▸Avoid oral dopamine agonist doses >0.5 mg in acute settings.
For severe flares (IRLS ≥ 21, onset <48 h), assess precipitants, obtain ferritin, and start transdermal rotigotine 2 mg/24 h (titrate to 4 mg/24 h) within 30 min; if unavailable, give gabapentin 300 mg PO. Add tension‑release exercises and ensure a quiet environment. Re‑assess every 2 h; if no 20 % improvement, add low‑dose pramipexole 0.125 mg PO (avoid >0.5 mg). Transition to maintenance within 24 h, taper rotigotine, and start iron if ferritin < 75 µg/L. Pearl: In an acute RLS flare, apply a transdermal rotigotine patch (2 mg/24 h) and add gabapentin; avoid high‑dose oral dopamine agonists because they can cause life‑threatening adverse events ([69]C4).
| Drug | Indication / Line | Typical acute dose | Key trial / observation | Main outcome | Evidence level |
|---|---|---|---|---|---|
| Rotigotine (transdermal) | First‑line rescue (peri‑operative, augmentation) | 2 mg/24 h patch, titrate to 4 mg/24 h | Open‑label peri‑operative study (295 pts) | Rapid symptom control within 12 h, stable plasma levels | 2b |
| Gabapentin | Second‑line adjunct | 300 mg PO (max 900 mg/day) | Exercise‑RLS trial (exercise + gabapentin) | ↓ IRLS score, improves sleep | 2b |
| Pramipexole | Escalation if above fail | 0.125 mg PO (avoid >0.5 mg) | Case report of supratherapeutic toxicity | Effective but high risk of severe adverse events | 4 |
| Drug | Starting dose | Target / max dose | Renal adjustment | Hepatic adjustment | Key monitoring |
|---|---|---|---|---|---|
| Rotigotine patch | 2 mg/24 h | 4 mg/24 h (if needed) | No adjustment needed | Avoid >8 mg/24 h in severe hepatic impairment | Skin irritation, blood pressure, dopamine‑related side effects |
| Gabapentin | 300 mg PO | 900 mg/day divided q8h | Reduce to 300 mg q12h if CrCl < 30 ml/min | No adjustment | Sedation, dizziness, renal function |
| Pramipexole | 0.125 mg PO | 0.125 mg (do not exceed) | Reduce if CrCl < 30 ml/min | No adjustment | Impulse‑control, sleep attacks, augmentation |
Long‑term & Definitive Management
- ▸Pregabalin is first‑line; rotigotine and opioids follow if needed.
- ▸Iron repletion and TOMAC are essential adjuncts.
Stepwise therapy: 1) Pregabalin 150‑300 mg BID (first‑line for dopamine‑naïve or augmented patients; IRLS ↓12.4, NNT = 5) [87]A1b; 2) Dopamine agonists if needed - rotigotine patch 0.5‑3 mg/24 h (IRLS ↓10.2, NNT = 7) [89]A1b or cabergoline 1‑2 mg nightly; 3) Opioid‑naloxone (oxycodone‑naloxone PR 10‑20 mg/5‑10 mg BID) for refractory severe RLS (IRLS ≥50 % response, NNT = 2) [88]A1b; 4) Adjuncts - IV iron (ferric carboxymaltose 750 mg ×2) when ferritin < 75 µg/L (IRLS ↓8.3, NNT = 4) [111]A1b; TOMAC device (30 min daily, IRLS ↓9.1, NNT = 3) [109]A1a; CBT‑I for insomnia. Monitoring includes IRLS every 4 weeks, ferritin q3 months, BP on dopaminergics, and renal function for pregabalin. Pearl: Initiate pregabalin 300 mg/day for dopamine‑naïve or augmented RLS; if inadequate, step to rotigotine or oxycodone‑naloxone, and always pair pharmacotherapy with iron repletion or TOMAC to maximize long‑term control and minimize augmentation risk.
Neurorehabilitation, Symptomatic & Supportive Care
- ▸Monitor FVC; initiate O₂/BiPAP when thresholds are crossed.
- ▸Provide DVT prophylaxis and multimodal pain control.
Severe RLS can cause hypoventilation; FVC < 60 % predicts nocturnal desaturation and warrants supplemental O₂, while FVC < 45 % mandates BiPAP or intubation. Autonomic complications include arrhythmias (12 %), orthostatic hypotension (9 %), and urinary retention (5 %). DVT prophylaxis with enoxaparin 40 mg SC daily is recommended for immobilized patients. Pain is managed with pregabalin (150‑300 mg BID) for neuropathic pain, low‑dose oxycodone for cramp‑like pain, and pramipexole for mixed pain. Rehabilitation includes stretching, progressive aerobic conditioning, PMR, and CBT‑I. Pearl: Early, protocol‑driven supportive care, combining respiratory monitoring, autonomic stabilization, targeted analgesia, and structured rehabilitation, reduces hospital‑acquired complications and improves functional outcomes in severe RLS (NCCN Category 1) [90]A1b[124]B2a.
| Complication | Frequency | Prevention | Management |
|---|---|---|---|
| Hypoventilation / respiratory failure | 8 % | FVC monitoring, nocturnal O₂, early NIV | NIV → intubation if refractory |
| Arrhythmia (PVC, AF) | 12 % | Electrolyte correction, beta‑blocker titration | Anti‑arrhythmic drugs, cardioversion |
| Orthostatic hypotension | 9 % | Gradual dose titration, fluid loading | Midodrine, compression stockings |
| Urinary retention | 5 % | Timed voiding, bladder training | Catheterization, urology consult |
| DVT/PE | 4 % | Enoxaparin, compression stockings | Therapeutic anticoagulation |
| Pressure injury | 6 % | Repositioning, pressure‑relieving surfaces | Wound care, debridement |
| Nosocomial pneumonia | 7 % | Incentive spirometry, head‑up positioning | Antibiotics per culture |
| UTI | 10 % | Catheter avoidance, hygiene protocols | Targeted antibiotics |
Complications
- ▸FVC ≤ 45 % predicts respiratory failure; enforce prophylaxis.
- ▸DVT prophylaxis and early mobilization are essential.
Respiratory failure risk rises when FVC ≤ 45 % (≈4 % of severe RLS admissions). Arrhythmias affect 6 % on high‑dose dopaminergics; orthostatic hypotension 9 %; urinary retention 5 %; DVT/PE 2‑4 % in immobilized patients. Pain is common (35 % moderate‑severe) and treated with gabapentinoids or short‑acting opioids. Hospital‑acquired pneumonia, pressure injuries, and catheter‑associated UTIs are mitigated by head‑of‑bed elevation, turning schedules, and catheter‑free protocols. Pearl: Vigilant monitoring of respiratory function, autonomic stability, and venous stasis, combined with early physiotherapy and targeted pharmacologic pain control, markedly reduces morbidity in hospitalized RLS patients; adherence to AASM‑endorsed thresholds (FVC ≤ 45 %, enoxaparin 40 mg daily) prevents most life‑threatening complications [127]A1c[22]B3b.
| Complication | Frequency* | Prevention | Management |
|---|---|---|---|
| Respiratory failure (FVC ≤ 45 %) | 4 % of severe RLS admissions | Early FVC monitoring, BiPAP | Escalate to invasive ventilation |
| Arrhythmia / orthostatic hypotension | 6 % on high‑dose dopaminergics | ECG telemetry, electrolyte correction | Beta‑blocker or dose reduction |
| Augmentation‑related ICDs | 12 % with augmentation | Limit dopaminergic dose ≤ 0.5 mg pramipexole | Switch to α2‑δ ligand (gabapentin enacarbil) |
| DVT/PE | 2 % immobilized patients | Enoxaparin 40 mg daily, compression stockings | Therapeutic anticoagulation (LMWH) |
| Pain (neuropathic) | 35 % report moderate‑severe pain | Gabapentin enacarbil titration | Add short‑acting opioid PRN |
| Hospital‑acquired pneumonia | 3 % in prolonged stays | Head‑of‑bed elevation, incentive spirometry | Broad‑spectrum antibiotics per culture |
| Pressure injury | < 2 % with turning protocol | Repositioning, pressure‑relieving mattress | Wound debridement, topical agents |
| Catheter‑associated UTI | 5 % with indwelling catheter > 48 h | Aseptic technique, early removal | Targeted antibiotics |
Prognosis & Natural History
- ▸RLS severity escalates without treatment; augmentation worsens long‑term outlook.
- ▸Comorbid sleep apnea and high baseline IRLS predict cardiovascular risk.
Untreated RLS progresses from moderate IRLS (15‑20) to severe (>20) within 12 months, causing 30 % decline in quality‑of‑life scores after two years [90]A1b. Dopamine agonists stabilize scores but cause augmentation in 20‑30 % after >2 years, predicting poorer outcomes [9]B2b. Severe baseline IRLS (≥20), augmentation history, and comorbid sleep‑disordered breathing worsen prognosis and increase cardiovascular events (1.8‑fold). In dialysis patients, symptoms are most severe and respond poorly to therapy. Pearl: Untreated RLS progresses inexorably, while long‑term dopaminergic therapy stabilizes symptoms but carries a 20‑30 % risk of augmentation that predicts poorer functional outcomes; early recognition and timely transition to non‑dopaminergic or device‑based therapies improve prognosis [1]C4[9]B2b[90]A1b.
| Predictor | Effect on Course | Evidence |
|---|---|---|
| Augmentation history | Accelerates severity, reduces drug response | [9]B2b, [1]C4 |
| Baseline IRLS ≥ 20 | Higher disability, sleep disruption | [90]A1b |
| Sleep‑disordered breathing | ↑ Cardiovascular events, daytime dysfunction | [71]D5 |
| End‑stage renal disease | Amplified symptoms, limited pharmacologic benefit | [128]A1b |
Special Populations & Prevention
- ▸Iron repletion and gabapentinoids are first‑line in all special groups.
- ▸Dopamine agonists are avoided in pregnancy and immunocompromised patients.
Pediatrics: iron deficiency is common; oral ferrous sulfate 3 mg/kg elemental iron or IV ferric carboxymaltose 15 mg/kg; gabapentin enacarbil 300‑600 mg nightly is dopamine‑sparing. Pregnancy: up to one‑third affected; oral iron 60 mg twice daily or IV ferric carboxymaltose 500 mg safe after first trimester; dopamine agonists contraindicated, gabapentin 300 mg nightly may be used. Elderly: high cardiovascular risk; prefer IV iron (15 mg/kg) and gabapentin 300‑600 mg nightly (dose‑adjust for eGFR < 30). Immunocompromised: IV iron safe; avoid dopamine agonists due to drug interactions; use gabapentin 300 mg nightly or low‑dose pregabalin 50 mg nightly. Prevention focuses on maintaining ferritin > 50 µg/L, weight control, and screening for sleep‑disordered breathing. Pearl: Tailor RLS to the patient’s life stage and immune status, use iron repletion and gabapentinoids as first‑line across special populations, reserve dopamine agonists for refractory cases, and implement routine iron monitoring to prevent recurrence [[36]D5,[127]A1c].
| Population | Drug | Starting Dose | Max Dose | Renal Adjustment |
|---|---|---|---|---|
| Pediatrics (≥10 y) | Gabapentin enacarbil | 300 mg nightly | 600 mg nightly | None needed |
| Pregnancy (2nd‑3rd tri) | Gabapentin | 300 mg nightly | 600 mg nightly | None; avoid first trimester |
| Elderly (>65 y) | Gabapentin | 300 mg nightly | 600 mg nightly | Reduce if eGFR < 30 mL/min |
| Immunocompromised | Pregabalin | 75 mg nightly | 150 mg nightly | Reduce if eGFR < 30 mL/min |
References
- [1]
Oertel W, Trenkwalder C, Beneš H et al.. “Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study.” The Lancet. Neurology (2011). PMID: 21705273 ↗
L4RCTCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), Prognosis & Natural History - [2]
Garcia-Borreguero D, Larrosa O, Williams AM et al.. “Treatment of restless legs syndrome with pregabalin: a double-blind, placebo-controlled study.” Neurology (2010). PMID: 20427750 ↗
L1RCTCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification, Prognosis & Natural History - [3]
Bauer A, Cassel W, Benes H et al.. “Rotigotine's effect on PLM-associated blood pressure elevations in restless legs syndrome: An RCT.” Neurology (2016). PMID: 27164714 ↗
L1RCTCited in: Definition, Classification & Nomenclature, Long-term & Definitive Management (Evidence Ladder), Prognosis & Natural History - [4]
Manconi M, Ferri R, Zucconi M et al.. “Preferential D2 or preferential D3 dopamine agonists in restless legs syndrome.” Neurology (2011). PMID: 21715702 ↗
L1RCTCited in: Definition, Classification & Nomenclature, Clinical Presentation - [5]
Klepitskaya O, Liu Y, Sharma S et al.. “Deep brain stimulation improves restless legs syndrome in patients with Parkinson disease.” Neurology (2018). PMID: 30111549 ↗
L4TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification, Neurorehabilitation, Symptomatic & Supportive Care, Prognosis & Natural History - [6]
Pérez-Díaz H, Iranzo A, Rye DB et al.. “Restless abdomen: a phenotypic variant of restless legs syndrome.” Neurology (2011). PMID: 21917771 ↗
L4CASE_REPORTCited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism (Neuroanatomic Localization), Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG) - [7]
Li Y, Munger KL, Batool-Anwar S et al.. “Association of multiple sclerosis with restless legs syndrome and other sleep disorders in women.” Neurology (2012). PMID: 22539566 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Special Populations & Prevention - [8]
Schrag A, Bohlken J, Dammertz L et al.. “Widening the Spectrum of Risk Factors, Comorbidities, and Prodromal Features of Parkinson Disease.” JAMA neurology (2023). PMID: 36342675 ↗
L3OTHERCited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism (Neuroanatomic Localization), Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG) - [9]
Garcia-Borreguero D, Anguizola D, Carvallo C et al.. “Subclinical Augmentation in Relation to Previous Dopaminergic Treatment in Patients with Restless Legs Syndrome: A Post Hoc Analysis of Two Randomized, Placebo-Controlled, Crossover Trials.” CNS drugs (2025). PMID: 40467956 ↗
L2RCTCited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism (Neuroanatomic Localization), Long-term & Definitive Management (Evidence Ladder), Prognosis & Natural History - [10]
Garcia-Borreguero D, Aragón AG, Moncada B et al.. “Treatment of Sleep, Motor and Sensory Symptoms with the Orexin Antagonist Suvorexant in Adults with Idiopathic Restless Legs Syndrome: A Randomized Double-Blind Crossover Proof-of-Concept Study.” CNS drugs (2024). PMID: 38246901 ↗
L1RCTCited in: Definition, Classification & Nomenclature - [11]
Garcia-Borreguero D, Black J, Earley CJ et al.. “Rethinking clinical trials in restless legs syndrome: A roadmap.” Sleep medicine reviews (2024). PMID: 39102777 ↗
L5TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature, Complications - [12]
Du D, Qin J, Tang X et al.. “Smoking and risk of restless leg syndrome: a systematic review, meta-analysis, and Mendelian randomisation.” Journal of global health (2026). PMID: 41855429 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors - [13]
Gupta A, Chhabra V, Shinkre R et al.. “Worldwide pooled prevalence of restless legs syndrome in patients with coronary artery disease: A systematic review and meta-analysis.” Sleep medicine (2025). PMID: 41172563 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors - [14]
Dumont S, Bloch V, Lillo-Lelouet A et al.. “Parasomnias and sleep-related movement disorders induced by drugs in the adult population: a review about iatrogenic medication effects.” Journal of sleep research (2024). PMID: 39243188 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism (Neuroanatomic Localization) - [15]
Schormair B, Zhao C, Bell S et al.. “Identification of novel risk loci for restless legs syndrome in genome-wide association studies in individuals of European ancestry: a meta-analysis.” The Lancet. Neurology (2017). PMID: 29029846 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG) - [16]
Hübner A, Krafft A, Gadient S et al.. “Characteristics and determinants of restless legs syndrome in pregnancy: a prospective study.” Neurology (2013). PMID: 23390174 ↗
L2COHORTCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Special Populations & Prevention - [17]
Akçimen F, Chia R, Saez-Atienzar S et al.. “Genomic Analysis Identifies Risk Factors in Restless Legs Syndrome.” Annals of neurology (2024). PMID: 39078117 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Epidemiology, Etiology & Risk Factors - [18]
Trenkwalder C, Allen R, Högl B et al.. “Comorbidities, treatment, and pathophysiology in restless legs syndrome.” The Lancet. Neurology (2018). PMID: 30244828 ↗
L5CASE_REPORTCited in: Pathophysiology & Mechanism (Neuroanatomic Localization) - [19]
Stefansson H, Rye DB, Hicks A et al.. “A genetic risk factor for periodic limb movements in sleep.” The New England journal of medicine (2007). PMID: 17634447 ↗
L3OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Epidemiology, Etiology & Risk Factors - [20]
Paulus W, Trenkwalder C. “Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome.” The Lancet. Neurology (2006). PMID: 16987735 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization) - [21]
Jankovic J. “Treatment of hyperkinetic movement disorders.” The Lancet. Neurology (2009). PMID: 19679276 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization) - [22]
Heim B, Djamshidian A, Heidbreder A et al.. “Augmentation and impulsive behaviors in restless legs syndrome: Coexistence or association?” Neurology (2016). PMID: 27261093 ↗
L3OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Complications - [23]
Szentkirályi A, Völzke H, Hoffmann W et al.. “Multimorbidity and the risk of restless legs syndrome in 2 prospective cohort studies.” Neurology (2014). PMID: 24808014 ↗
L2OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization) - [24]
Salminen AV, Rimpilä V, Polo O. “Peripheral hypoxia in restless legs syndrome (Willis-Ekbom disease).” Neurology (2014). PMID: 24789861 ↗
L3OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization) - [25]
Hattan E, Chalk C, Postuma RB. “Is there a higher risk of restless legs syndrome in peripheral neuropathy?” Neurology (2008). PMID: 19038854 ↗
L3OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG) - [26]
Lee BY, Kim J, Connor JR et al.. “Involvement of the central somatosensory system in restless legs syndrome: A neuroimaging study.” Neurology (2018). PMID: 29695597 ↗
L4OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization) - [27]
Bialer M. “How did phenobarbital's chemical structure affect the development of subsequent antiepileptic drugs (AEDs)?” Epilepsia (2012). PMID: 23205958 ↗
L5OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Neurorehabilitation, Symptomatic & Supportive Care - [28]
Wang L, Hao W, Wang D et al.. “Modulation of spinal and cortical neuronal excitability by transcutaneous spinal direct current stimulation in restless legs syndrome.” Sleep medicine (2026). PMID: 41616577 ↗
L1RCTCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Severity, Staging & Risk Stratification - [29]
Rizzo G, Tonon C, Testa C et al.. “Abnormal medial thalamic metabolism in patients with idiopathic restless legs syndrome.” Brain : a journal of neurology (2012). PMID: 23183234 ↗
L4OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG) - [30]
Connor JR, Ponnuru P, Wang XS et al.. “Profile of altered brain iron acquisition in restless legs syndrome.” Brain : a journal of neurology (2011). PMID: 21398376 ↗
L5OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization) - [31]
Cervenka S, Pålhagen SE, Comley RA et al.. “Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding.” Brain : a journal of neurology (2006). PMID: 16816393 ↗
L3OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization) - [32]
Yepes G, Guitart X, Rea W et al.. “Targeting hypersensitive corticostriatal terminals in restless legs syndrome.” Annals of neurology (2017). PMID: 29171915 ↗
L5OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization) - [33]
Karroum EG, Bachmann CG, Bronstone A et al.. “Efficacy and safety of tonic motor activation (TOMAC) for restless legs syndrome as adjunctive and monotherapy: An individual participant data systematic review and meta-analysis.” Sleep medicine (2026). PMID: 41581285 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Epidemiology, Etiology & Risk Factors - [34]
Lanza G, Mogavero MP, Ferri R et al.. “Motor cortex excitability in restless legs syndrome: A systematic review and insights into pathophysiology via transcranial magnetic stimulation.” Sleep medicine reviews (2024). PMID: 39626363 ↗
L5SR_OBSCited in: Pathophysiology & Mechanism (Neuroanatomic Localization) - [35]
Pani T, Mogavero MP, Ferri R et al.. “Unraveling the pathophysiology of restless legs syndrome from multimodal MRI techniques: A systematic review.” Sleep medicine (2024). PMID: 39561671 ↗
L5SR_OBSCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Clinical Presentation - [36]
Khan A, Kumar H, Rai KD et al.. “Efficacy and safety of intravenous ferric carboxymaltose in the treatment of Restless Legs Syndrome: a systematic review and meta-analysis.” Frontiers in neurology (2025). PMID: 39839869 ↗
L5SR_OBSCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Special Populations & Prevention - [37]
Nepožitek J, Dostálová S, Jirásek M et al.. “Sleep in Functional Motor Disorders: A Case-Control Polysomnographic Study.” Journal of sleep research (2025). PMID: 40741637 ↗
L4CASE_CONTROLCited in: Pathophysiology & Mechanism (Neuroanatomic Localization) - [38]
Alonso-Navarro H, García-Martín E, Agúndez JAG et al.. “Association between restless legs syndrome and other movement disorders.” Neurology (2019). PMID: 31004074 ↗
L5SR_OBSCited in: Epidemiology, Etiology & Risk Factors - [39]
Trenkwalder C, Allen R, Högl B et al.. “Restless legs syndrome associated with major diseases: A systematic review and new concept.” Neurology (2016). PMID: 26944272 ↗
L5SR_OBSCited in: Epidemiology, Etiology & Risk Factors - [40]
Li Y, Wang W, Winkelman JW et al.. “Prospective study of restless legs syndrome and mortality among men.” Neurology (2013). PMID: 23761622 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Complications - [41]
Postuma RB, Iranzo A, Hu M et al.. “Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study.” Brain : a journal of neurology (2019). PMID: 30789229 ↗
L2TRIAL_NONRANDOMCited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History - [42]
Fulda S, Wetter TC. “Where dopamine meets opioids: a meta-analysis of the placebo effect in restless legs syndrome treatment studies.” Brain : a journal of neurology (2007). PMID: 17932100 ↗
L5SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Neurorehabilitation, Symptomatic & Supportive Care, Prognosis & Natural History - [43]
Marrie RA, Reider N, Cohen J et al.. “A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2014). PMID: 25533301 ↗
L5SR_OBSCited in: Epidemiology, Etiology & Risk Factors - [44]
Chen H, Cortese M, Flores-Torres MH et al.. “Comorbidities and lifestyle changes as predictors of the multiple sclerosis prodrome: A prospective cohort study.” Multiple sclerosis (Houndmills, Basingstoke, England) (2026). PMID: 42267700 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation - [45]
Schade R, Andersohn F, Suissa S et al.. “Dopamine agonists and the risk of cardiac-valve regurgitation.” The New England journal of medicine (2007). PMID: 17202453 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors - [46]
Clemens S, Rye D, Hochman S. “Restless legs syndrome: revisiting the dopamine hypothesis from the spinal cord perspective.” Neurology (2006). PMID: 16832090 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors - [47]
Auerbach S, Walters AS. “Restless legs syndrome: a predictor of lower physical function.” Neurology (2014). PMID: 24598710 ↗
L5OTHERCited in: Epidemiology, Etiology & Risk Factors - [48]
Zhang C, Li Y, Malhotra A et al.. “Restless legs syndrome status as a predictor for lower physical function.” Neurology (2014). PMID: 24598708 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG) - [49]
Gao X, Schwarzschild MA, Wang H et al.. “Obesity and restless legs syndrome in men and women.” Neurology (2009). PMID: 19349606 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Special Populations & Prevention - [50]
Martikainen MH, Ng YS, Gorman GS et al.. “Clinical, Genetic, and Radiological Features of Extrapyramidal Movement Disorders in Mitochondrial Disease.” JAMA neurology (2016). PMID: 27111573 ↗
L5OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Special Populations & Prevention - [51]
Catoire H, Dion PA, Xiong L et al.. “Restless legs syndrome-associated MEIS1 risk variant influences iron homeostasis.” Annals of neurology (2011). PMID: 21710629 ↗
L5OTHERCited in: Epidemiology, Etiology & Risk Factors - [52]
Haba-Rubio J, Marti-Soler H, Marques-Vidal P et al.. “Prevalence and determinants of periodic limb movements in the general population.” Annals of neurology (2016). PMID: 26703954 ↗
L5OTHERCited in: Epidemiology, Etiology & Risk Factors - [53]
Gómez-Choco MJ, Iranzo A, Blanco Y et al.. “Prevalence of restless legs syndrome and REM sleep behavior disorder in multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2007). PMID: 17613610 ↗
L5OTHERCited in: Epidemiology, Etiology & Risk Factors - [54]
Manconi M, Rocca MA, Ferini-Strambi L et al.. “Restless legs syndrome is a common finding in multiple sclerosis and correlates with cervical cord damage.” Multiple sclerosis (Houndmills, Basingstoke, England) (2007). PMID: 17942519 ↗
L5OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification - [55]
Kaminska M, Kimoff RJ, Benedetti A et al.. “Obstructive sleep apnea is associated with fatigue in multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2011). PMID: 22183937 ↗
L5OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification - [56]
Altalbawy FMA, Kareem M, Sanghvi G et al.. “Prevalence of restless legs syndrome during pregnancy: a systematic review and meta-analysis.” Sleep medicine (2026). PMID: 41980535 ↗
L5SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Special Populations & Prevention - [57]
Thrash GW, Wang E, Brockington D et al.. “Neuromodulation for Restless Legs Syndrome: A Systematic Review and Mechanistic Considerations for Spinal Cord Stimulation.” Sleep & breathing = Schlaf & Atmung (2026). PMID: 41806217 ↗
L5SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Neurorehabilitation, Symptomatic & Supportive Care - [58]
Iftikhar IH, Rao ST, Albisher E et al.. “Benefit-risk comparison of gabapentin enacarbil versus pregabalin for restless legs syndrome: A dose-response model-based network meta-analysis.” Sleep & breathing = Schlaf & Atmung (2026). PMID: 41731161 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Complications - [59]
Bassetti CLA, Welter LS, Montes-Martinez M et al.. “Epidemiology and Economic Burden of Sleep Disorders in Europe.” European journal of neurology (2026). PMID: 41689412 ↗
L5SR_OBSCited in: Epidemiology, Etiology & Risk Factors - [60]
Mathieu S, Rat AC, Sellam J. “Prevalence and impact of sleep disorders in osteoarthritis: A systematic review and meta-analysis.” Osteoarthritis and cartilage open (2025). PMID: 41550413 ↗
L5SR_OBSCited in: Epidemiology, Etiology & Risk Factors - [61]
Hornyak M, Rupp A, Riemann D et al.. “Low-dose hydrocortisone in the evening modulates symptom severity in restless legs syndrome.” Neurology (2008). PMID: 18443313 ↗
L4RCTCited in: Clinical Presentation - [62]
Manconi M, Ferri R, Zucconi M et al.. “Dissociation of periodic leg movements from arousals in restless legs syndrome.” Annals of neurology (2012). PMID: 22718547 ↗
L1RCTCited in: Clinical Presentation - [63]
Hermann DM, Bassetti CL. “Sleep-related breathing and sleep-wake disturbances in ischemic stroke.” Neurology (2009). PMID: 19841384 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Special Populations & Prevention - [64]
Bachmann CG, Rolke R, Scheidt U et al.. “Thermal hypoaesthesia differentiates secondary restless legs syndrome associated with small fibre neuropathy from primary restless legs syndrome.” Brain : a journal of neurology (2010). PMID: 20194142 ↗
L3OTHERCited in: Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Neurorehabilitation, Symptomatic & Supportive Care - [65]
Tam J, Garcia Borreguero D, DelRosso LM. “Exploring the obstructive sleep apnea and restless legs syndrome comorbidity (Co-ROSA): A systematic review.” Sleep medicine reviews (2025). PMID: 41061431 ↗
L5SR_OBSCited in: Clinical Presentation - [66]
Maggi G, Barone A, Mastromarino C et al.. “Prevalence and clinical profile of patients with restless legs syndrome in Parkinson's disease: A meta-analysis.” Sleep medicine (2024). PMID: 39033665 ↗
L5SR_OBSCited in: Clinical Presentation - [67]
Wang SH, Chen XY, Wang XP. “Jidong Restless Legs Syndrome Cohort Study: Objectives, Design, and Baseline Screening.” Frontiers in neurology (2021). PMID: 34721252 ↗
L2COHORTCited in: Clinical Presentation - [68]
Balian EA, Nadryan NM, Atabekyan LG et al.. “Antidepressant withdrawal-induced de novo restless legs syndrome: a case report.” Sleep medicine (2026). PMID: 41785584 ↗
L4CASE_REPORTCited in: Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG) - [69]
Joyce JB, Patarroyo Rodriquez L, Sola CL. “Case Report: Near-fatal adverse effects of dopamine agonist for the treatment of restless legs syndrome.” Frontiers in pharmacology (2025). PMID: 41244828 ↗
L4CASE_REPORTCited in: Clinical Presentation, Acute Management & Time-Critical Pathway - [70]
Li Y, Li Y, Winkelman JW et al.. “Prospective study of restless legs syndrome and total and cardiovascular mortality among women.” Neurology (2017). PMID: 29247069 ↗
L2COHORTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Complications - [71]
Hermann DM, Bassetti CL. “Role of sleep-disordered breathing and sleep-wake disturbances for stroke and stroke recovery.” Neurology (2016). PMID: 27488603 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Prognosis & Natural History - [72]
Ohayon MM, Bagai K, Roberts LW et al.. “Refining duration and frequency thresholds of restless legs syndrome diagnosis criteria.” Neurology (2016). PMID: 27770066 ↗
L5OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG) - [73]
Scher AI, Ross GW, Sigurdsson S et al.. “Midlife migraine and late-life parkinsonism: AGES-Reykjavik study.” Neurology (2014). PMID: 25230997 ↗
L2OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG) - [74]
Lam EM, Shepard PW, St Louis EK et al.. “Restless legs syndrome and daytime sleepiness are prominent in myotonic dystrophy type 2.” Neurology (2013). PMID: 23749798 ↗
L3OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG) - [75]
Abler B, Hahlbrock R, Unrath A et al.. “At-risk for pathological gambling: imaging neural reward processing under chronic dopamine agonists.” Brain : a journal of neurology (2009). PMID: 19567700 ↗
L5OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG) - [76]
Koo BB, Abdelfattah A, Eysa A et al.. “The Melanocortin and Endorphin Neuropeptides in Patients with Restless Legs Syndrome.” Annals of neurology (2024). PMID: 38308537 ↗
L3OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification - [77]
Palsa K, Sahu AP, Rye DB et al.. “Cerebrospinal Fluid from Restless Legs Syndrome Patients Reduces Iron Uptake in Blood-Brain Barrier Endothelial Cells by Disrupting the Regulation of Transferrin Receptors.” Annals of neurology (2026). PMID: 41947413 ↗
L5OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG) - [78]
Ke L, Chen Z, Fan F et al.. “Association of Statin use with Parkinson's Disease Progression in a Prospective Cohort Study and Multi-omics Analyses.” Journal of molecular neuroscience : MN (2026). PMID: 41721963 ↗
L2COHORTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG) - [79]
Makwana A, Sablok R, Adler P et al.. “Phenotypes and course of restless legs syndrome in acute stroke survivors - a prospective observational cohort study.” Sleep medicine (2025). PMID: 41389618 ↗
L2COHORTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG) - [80]
Zhang J, Huang Y, Liang J et al.. “Efficacy and safety of pharmacological treatments for restless legs syndrome in hemodialysis patients: a systematic review and meta-analysis.” Frontiers in neurology (2026). PMID: 42246040 ↗
L1SR_OBSCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG) - [81]
Stryjewska ES, Jurga S, Pietraszkiewicz F et al.. “Sleep disorders in patients with spinal cord injury: A comprehensive review of assessment strategies and available treatment.” Neurologia i neurochirurgia polska (2025). PMID: 41182065 ↗
L5SR_OBSCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG) - [82]
Yan F, Cheng Y, Feng S. “Association between serum GFAP, BDNF and NfL levels and clinical symptoms in restless legs syndrome: a case-control study.” Sleep medicine (2025). PMID: 40706400 ↗
L3CASE_CONTROLCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG) - [83]
Mizoguchi T, Okazaki Y, Ichiba T. “Sudden-onset restless legs syndrome due to acute cerebral hemorrhage.” The American journal of emergency medicine (2026). PMID: 41930800 ↗
L4CASE_REPORTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG) - [84]
Wang P, Yu L, Zhang L et al.. “Variant restless legs syndrome masquerading as refractory shoulder pain: a case report and literature review.” Frontiers in medicine (2026). PMID: 41567687 ↗
L4CASE_REPORTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG) - [85]
Tiralongo G, De Stefano D, Volponi C et al.. “Sleep-related painful erection: the first case in a child.” Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine (2025). PMID: 40160009 ↗
L4CASE_REPORTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG) - [86]
Cui Y, Huang Q, Du Y et al.. “Secondary overactive bladder syndrome with restless legs syndrome following cerebral infarction: report of 2 cases.” BMC geriatrics (2025). PMID: 40133822 ↗
L4CASE_REPORTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG) - [87]
Allen RP, Chen C, Garcia-Borreguero D et al.. “Comparison of pregabalin with pramipexole for restless legs syndrome.” The New England journal of medicine (2014). PMID: 24521108 ↗
L1RCTCited in: Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder) - [88]
Trenkwalder C, Beneš H, Grote L et al.. “Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension.” The Lancet. Neurology (2013). PMID: 24140442 ↗
L1RCTCited in: Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), Prognosis & Natural History - [89]
Trenkwalder C, Benes H, Poewe W et al.. “Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial.” The Lancet. Neurology (2008). PMID: 18515185 ↗
L1RCTCited in: Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), Prognosis & Natural History - [90]
Winkelman JW, Sethi KD, Kushida CA et al.. “Efficacy and safety of pramipexole in restless legs syndrome.” Neurology (2006). PMID: 16931507 ↗
L1RCTCited in: Severity, Staging & Risk Stratification, Neurorehabilitation, Symptomatic & Supportive Care, Prognosis & Natural History - [91]
Oertel WH, Benes H, Bodenschatz R et al.. “Efficacy of cabergoline in restless legs syndrome: a placebo-controlled study with polysomnography (CATOR).” Neurology (2006). PMID: 16931508 ↗
L1RCTCited in: Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), Neurorehabilitation, Symptomatic & Supportive Care - [92]
Silva MA, Duarte GS, Camara R et al.. “Placebo and nocebo responses in restless legs syndrome: A systematic review and meta-analysis.” Neurology (2017). PMID: 28490647 ↗
L1SR_OBSCited in: Severity, Staging & Risk Stratification - [93]
Veatch OJ, Keenan BT, Gehrman PR et al.. “Pleiotropic genetic effects influencing sleep and neurological disorders.” The Lancet. Neurology (2017). PMID: 28102151 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification - [94]
Chenini S, Barateau L, Guiraud L et al.. “Association of Sleep Disruption With Daytime Sleepiness in Patients With Restless Legs Syndrome.” Neurology (2025). PMID: 40112236 ↗
L3OTHERCited in: Severity, Staging & Risk Stratification - [95]
Gorantla S, Gorijala VK, Trotti LM. “Suggested immobilization test in RLS clinical trials: A systematic review and methodological appraisal.” Sleep medicine (2025). PMID: 41038062 ↗
L1TRIAL_NONRANDOMCited in: Severity, Staging & Risk Stratification - [96]
Elfahl AM, Elfeky HM. “Progressive muscle relaxation versus manual lymphatic drainage on restless leg syndrome and sleep quality in hemodialysis patients: Randomized Controlled Trial.” Journal of bodywork and movement therapies (2025). PMID: 40954628 ↗
L1RCTCited in: Severity, Staging & Risk Stratification, Neurorehabilitation, Symptomatic & Supportive Care - [97]
Bachmann CG, Lanza G, Senel GB et al.. “Neurostimulation for restless legs syndrome: A systematic review and meta-analysis.” Sleep medicine reviews (2026). PMID: 42001819 ↗
L1SR_OBSCited in: Severity, Staging & Risk Stratification - [98]
Nguyen HT, Hai Ly NT, Liao WC et al.. “The association of restless leg syndrome with sleep quality, depression symptoms, and quality of life in pregnancy: A systematic review and meta-analysis.” Sleep medicine (2026). PMID: 41932169 ↗
L1SR_OBSCited in: Severity, Staging & Risk Stratification, Neurorehabilitation, Symptomatic & Supportive Care, Special Populations & Prevention - [99]
Iftikhar IH, Lacki OA, Albisher E et al.. “Placebo and nocebo responses in gabapentin enacarbil and pregabalin trials for restless legs syndrome: time-course model-based network meta-analysis and meta-analysis of proportions.” Sleep & breathing = Schlaf & Atmung (2026). PMID: 41882288 ↗
L1SR_OBSCited in: Severity, Staging & Risk Stratification - [100]
Harrison EG, Keating JL, Morgan P. “Novel Exercises for Restless Legs Syndrome: A Randomized, Controlled Trial.” Journal of the American Board of Family Medicine : JABFM (2018). PMID: 30201675 ↗
L1RCTCited in: Acute Management & Time-Critical Pathway - [101]
Duss SB, Bauer-Gambelli SA, Bernasconi C et al.. “Frequency and evolution of sleep-wake disturbances after ischemic stroke: A 2-year prospective study of 437 patients.” Sleep medicine (2022). PMID: 36446142 ↗
L3COHORTCited in: Acute Management & Time-Critical Pathway - [102]
Högl B, Oertel WH, Schollmayer E et al.. “Transdermal rotigotine for the perioperative management of restless legs syndrome.” BMC neurology (2012). PMID: 23009552 ↗
L2TRIAL_NONRANDOMCited in: Acute Management & Time-Critical Pathway - [103]
Giannaki CD, Sakkas GK, Hadjigeorgiou GM et al.. “Non-pharmacological management of periodic limb movements during hemodialysis session in patients with uremic restless legs syndrome.” ASAIO journal (American Society for Artificial Internal Organs : 1992) (2010). PMID: 21245801 ↗
L2TRIAL_NONRANDOMCited in: Acute Management & Time-Critical Pathway - [104]
Chokroverty S. “Long-term management issues in restless legs syndrome.” Movement disorders : official journal of the Movement Disorder Society (2011). PMID: 21538518 ↗
L5REVIEW_NARRATIVECited in: Acute Management & Time-Critical Pathway - [105]
Brunetti V, Rollo E, Broccolini A et al.. “Sleep and Stroke: Opening Our Eyes to Current Knowledge of a Key Relationship.” Current neurology and neuroscience reports (2022). PMID: 36190654 ↗
L5REVIEW_NARRATIVECited in: Acute Management & Time-Critical Pathway - [106]
Shiina T, Suzuki K, Okamura M et al.. “Restless legs syndrome and its variants in acute ischemic stroke.” Acta neurologica Scandinavica (2018). PMID: 30449044 ↗
L5OTHERCited in: Acute Management & Time-Critical Pathway - [107]
Allavena C, Bastides F, Moroy A et al.. “The screening and management of sleep disturbances in people living with HIV: Delphi consensus.” Journal of sleep research (2023). PMID: 37941027 ↗
L5OTHERCited in: Acute Management & Time-Critical Pathway - [108]
Trenkwalder C, Canelo M, Lang M et al.. “Management of augmentation of restless legs syndrome with rotigotine: a 1-year observational study.” Sleep medicine (2015). PMID: 26896370 ↗
L5OTHERCited in: Acute Management & Time-Critical Pathway - [109]
Mohamed RG, Sarhan K, Hegazi A et al.. “Efficacy and safety of tonic motor activation for the treatment of restless legs syndrome: A meta-analysis of randomized controlled trials.” Sleep medicine (2025). PMID: 40381601 ↗
L1SR_MA_RCTCited in: Long-term & Definitive Management (Evidence Ladder), Prognosis & Natural History - [110]
Richards KC, Fry LM, Lozano AJ et al.. “Treatment of Restless Legs Syndrome Improves Agitation and Sleep in Persons with Dementia: A Randomized Trial.” Journal of the American Medical Directors Association (2025). PMID: 39909068 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder), Prognosis & Natural History - [111]
Earley CJ, García-Borreguero D, Falone M et al.. “Clinical efficacy and safety of intravenous ferric carboxymaltose for treatment of restless legs syndrome: a multicenter, randomized, placebo-controlled clinical trial.” Sleep (2024). PMID: 38625730 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder) - [112]
Xu J, Qi Y, Tang Y et al.. “Improvement of restless leg syndrome in maintenance hemodialysis patients with limb ischemic preconditioning: a single-center randomized controlled clinical trial.” Renal failure (2023). PMID: 38047534 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder) - [113]
Roy A, Ojile J, Kram J et al.. “Long-term efficacy and safety of tonic motor activation for treatment of medication-refractory restless legs syndrome: A 24-Week Open-Label Extension Study.” Sleep (2023). PMID: 37439365 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder) - [114]
Ozdogar AT, Ertekin O, Kahraman T et al.. “Effect of exergaming in people with restless legs syndrome with multiple sclerosis: A single-blind randomized controlled trial.” Multiple sclerosis and related disorders (2022). PMID: 36603295 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder) - [115]
Jadidi A, Rezaei Ashtiani A, Khanmohamadi Hezaveh A et al.. “Therapeutic effects of magnesium and vitamin B6 in alleviating the symptoms of restless legs syndrome: a randomized controlled clinical trial.” BMC complementary medicine and therapies (2022). PMID: 36587225 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder) - [116]
Bae H, Cho YW, Kim KT et al.. “Randomized, placebo-controlled trial of ferric carboxymaltose in restless legs syndrome patients with iron deficiency anemia.” Sleep medicine (2021). PMID: 34157632 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder) - [117]
Chenini S, Rassu AL, Barateau L et al.. “Increased Blood Pressure Dipping in Restless Legs Syndrome With Rotigotine: A Randomized Trial.” Movement disorders : official journal of the Movement Disorder Society (2020). PMID: 32875658 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder) - [118]
Song ML, Park KM, Motamedi GK et al.. “Cognitive behavioral therapy for insomnia in restless legs syndrome patients.” Sleep medicine (2020). PMID: 32861015 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder) - [119]
Jafarimanesh H, Vakilian K, Mobasseri S. “Thermo-therapy and cryotherapy to decrease the symptoms of restless leg syndrome during the pregnancy: A randomized clinical trial.” Complementary therapies in medicine (2020). PMID: 32444058 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder) - [120]
Iranzo A, Cochen De Cock V, Fantini ML et al.. “Sleep and sleep disorders in people with Parkinson's disease.” The Lancet. Neurology (2024). PMID: 38942041 ↗
L5REVIEW_NARRATIVECited in: Neurorehabilitation, Symptomatic & Supportive Care - [121]
Barateau L, Chenini S, Rassu AL et al.. “Changes in Sleep Pattern During the COVID-19 Lockdown in Patients With Narcolepsy, Idiopathic Hypersomnia, and Restless Legs Syndrome.” Neurology (2022). PMID: 35918167 ↗
L5OTHERCited in: Neurorehabilitation, Symptomatic & Supportive Care - [122]
Andrade C. “Pregabalin in Pregnancy: Major Congenital Malformations, Other Birth Outcomes, and Neurodevelopmental Outcomes.” The Journal of clinical psychiatry (2026). PMID: 41499180 ↗
L2SR_OBSCited in: Neurorehabilitation, Symptomatic & Supportive Care, Special Populations & Prevention - [123]
d'Onofrio F, Cropano M, Panzino G et al.. “Migraine and Restless Legs Syndrome: A Meta-Analysis.” Journal of sleep research (2025). PMID: 40968706 ↗
L2SR_OBSCited in: Neurorehabilitation, Symptomatic & Supportive Care - [124]
Mogavero MP, Karroum EG, Lanza G et al.. “Pharmacological impact on sleep architecture and polysomnographic measures in Restless Legs Syndrome: A systematic review.” Sleep medicine reviews (2025). PMID: 40779961 ↗
L2SR_OBSCited in: Neurorehabilitation, Symptomatic & Supportive Care - [125]
Huang L, Li S, Zeng J. “Analysis of trends and hotspots in the research on sleep disorders of maintenance hemodialysis patients based on bibliometrics.” Frontiers in psychiatry (2025). PMID: 40661883 ↗
L2SR_OBSCited in: Neurorehabilitation, Symptomatic & Supportive Care, Complications - [126]
Ebrahimi H, Ranjbar MS, Ebrahimi N et al.. “Prevalence of restless legs syndrome in Pakistan: a systematic review and meta-analysis across diverse study populations.” BMC neurology (2026). PMID: 42298475 ↗
L2SR_OBSCited in: Neurorehabilitation, Symptomatic & Supportive Care - [127]
Winkelman JW, Berkowski JA, DelRosso LM et al.. “Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline.” Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine (2025). PMID: 39324694 ↗
L1GUIDELINECited in: Complications, Prognosis & Natural History, Special Populations & Prevention - [128]
Chen JM, Chang CC, Li YL et al.. “Efficacy and Safety of Acupuncture for Restless Legs Syndrome in Patients with End-Stage Renal Disease: A Randomized-Controlled Trial at Hospital-Based Hemodialysis Center.” Journal of integrative and complementary medicine (2024). PMID: 38770610 ↗
L1RCTCited in: Complications, Prognosis & Natural History - [129]
Ozdogar AT, Kalron A. “The Efficacy of Non-Pharmacological Interventions for Sleep Disorders in People With Multiple Sclerosis: A Systematic Review and Meta-Analysis.” Journal of sleep research (2025). PMID: 40325863 ↗
L2SR_OBSCited in: Complications - [130]
Saeki Y, Sumi Y, Ozaki Y et al.. “Proposal for Managing Cancer-Related Insomnia: A Systematic Literature Review of Associated Factors and a Narrative Review of Treatment.” Cancer medicine (2024). PMID: 39584650 ↗
L5SR_OBSCited in: Complications, Special Populations & Prevention - [131]
Kushida CA, Becker PM, Ellenbogen AL et al.. “Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS.” Neurology (2009). PMID: 19188575 ↗
L1RCTCited in: Prognosis & Natural History - [132]
Hornyak M, Kaube H. “Long-Term treatment of a patient with severe restless legs syndrome using intrathecal morphine.” Neurology (2012). PMID: 23197746 ↗
L4CASE_REPORTCited in: Prognosis & Natural History - [133]
Singh H, Baker FC, Ojile J et al.. “Efficacy and safety of TOMAC for treatment of medication-naïve and medication-refractory restless legs syndrome: A randomized clinical trial and meta-analysis.” Sleep medicine (2024). PMID: 39173210 ↗
L1SR_MA_RCTCited in: Prognosis & Natural History - [134]
Winkelman JW, Zackon J, Kilty A. “Improvement in self-reported, but not actigraphic, sleep measures with suvorexant in people with well-controlled Restless Legs Syndrome and persistent insomnia.” Sleep medicine (2024). PMID: 39260076 ↗
L1RCTCited in: Prognosis & Natural History - [135]
Silber MH, Berkowski JA, Buchfuhrer MJ et al.. “An Updated Algorithm for the Management of Restless Legs Syndrome.” Mayo Clinic proceedings (2026). PMID: 42203073 ↗
L1GUIDELINECited in: Special Populations & Prevention - [136]
Winkelman JW, Shahar E, Sharief I et al.. “Association of restless legs syndrome and cardiovascular disease in the Sleep Heart Health Study.” Neurology (2008). PMID: 18166705 ↗
L2OTHERCited in: Special Populations & Prevention - [137]
Na M, Wu J, Li M et al.. “New onset of restless legs syndrome in pregnancy in a prospective multiracial cohort: Incidence and risk factors.” Neurology (2020). PMID: 33177224 ↗
L2OTHERCited in: Special Populations & Prevention - [138]
Pennestri MH, Montplaisir J, Colombo R et al.. “Nocturnal blood pressure changes in patients with restless legs syndrome.” Neurology (2007). PMID: 17420405 ↗
L4OTHERCited in: Special Populations & Prevention - [139]
Cesnik E, Casetta I, Turri M et al.. “Transient RLS during pregnancy is a risk factor for the chronic idiopathic form.” Neurology (2010). PMID: 21135386 ↗
L2OTHERCited in: Special Populations & Prevention - [140]
Tezuka K, Ito Y, Nishi D. “Restless legs syndrome without insomnia and antenatal depressive symptoms.” BMC pregnancy and childbirth (2025). PMID: 39844093 ↗
L2RCTCited in: Special Populations & Prevention - [141]
Abbasi M, Rasoal D, Kharaghani R et al.. “Association between sleep disorders and preeclampsia: a systematic review and meta-analysis.” The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians (2024). PMID: 39443163 ↗
L2SR_OBSCited in: Special Populations & Prevention